Laboratory reports are available for selected lots. Check each report for its result and stated method.
GLP-3 R Retatrutide
≥98% Purity
Class-level spec; selected lots third-party tested
COA Available
Batch report on request · HPLC identity check
Size
10mg
= Lab report published
€39.99
1
Total: €39.99
Free shipping on orders over €200
- If a product does not match the specification on its published COA, contact us with your batch number: we investigate against the lot report and replace any product that fails it, at no cost to you.
- Contact us within 48 hours of delivery with photos of the outer box, inner packing, and any affected vials with labels legible. Confirmed transit damage is replaced at no cost to you.
3–7 days most of the EU · 10–14 Nordics/Baltics
Standard EU from €4.99 · core EU GLS €17.99 · Dispatched within 1–2 business days · Free shipping over €200 · no customs paperwork (EU).
How Paysera and SEPA work
- Pay: send a manual SEPA transfer using the IBAN we email you, or approve a SEPA transfer via Paysera where offered.
- We confirm — Paysera notifies us instantly, or we match a manual transfer when it arrives (usually 1 business day).
- We dispatch — confirmed orders typically ship within 1–2 business days.
Card payments are not currently offered.
Research-grade Retatrutide (triple agonist) for laboratory research applications. For research purposes only. Not for human consumption.
Volume Pricing
Applied automatically at checkout
| Quantity | Price Each | Total | Savings |
|---|---|---|---|
| 1 unit | €39.99 | €39.99 | — |
| 3+ | €37.99 | €113.97 | 5% off |
| 5+ Most Popular | €35.99 | €179.96 | 10% off |
| 10+ | €33.99 | €339.92 | 15% off |
Class-level specification on record; independent testing on selected lots.
Dispatched within 1–2 business days, shipping from €4.99 in the EU.
Ships across the EU plus Switzerland and the UK where permitted.
Retatrutide (GLP-3)
Retatrutide, frequently searched as buy glp-3 r (Retatrutide), is an investigational peptide targeting appetite, glucose regulation, and energy balance. Clinical studies show significant weight loss, improved fasting glucose and HbA1c, reduced appetite, and favorable metabolic markers, but long-term safety and appropriate clinical use remain under investigation and require healthcare supervision.
What Is Retatrutide?
Retatrutide, also known as LY3437943, is a synthetic triple-receptor agonist developed by Eli Lilly. It activates GLP-1, GIP and glucagon pathways. The informal label “GLP-3” does not identify a recognised hormone or scientific classification.
Development has progressed into Phase 3, with results reported from several studies. Retatrutide remains investigational and has not received regulatory approval for public use.
Significance in Scientific Research
The compound’s combined activity provides a basis for investigating how different signalling pathways interact. Laboratory experiments may examine binding, downstream responses, molecular interactions and peptide stability.
Researchers should distinguish these mechanistic questions from clinical outcomes. A response in a cell-based assay does not independently demonstrate weight loss, improved glucose control or effectiveness in people.
A Phase 2 study published in the New England Journal of Medicine reported substantial weight reduction in participants with obesity who did not have diabetes:
| Study measure | Reported finding |
|---|---|
| Treatment period | 48 weeks |
| Highest-dose group | Mean weight reduction of 24.2% |
| Placebo group | Mean weight reduction of 2.1% |
| Interpretation | Results apply to the studied population and treatment conditions |
These findings do not establish superiority over other medicines without an appropriate comparative study.
Mechanism: Three Signalling Targets
As a triple agonist, retatrutide combines activity at pathways involved in appetite, nutrient handling and energy balance. This distinguishes its pharmacological profile from that of a compound acting through GLP-1 alone.
| Target | Relevant experimental focus |
|---|---|
| GLP-1 receptor | Signalling associated with appetite and glucose-dependent insulin responses |
| GIP receptor | Responses involved in nutrient-dependent insulin secretion |
| Glucagon receptor | Pathways associated with hepatic metabolism and energy balance |
The contribution of each pathway depends on the experimental setting. Receptor expression, concentration and exposure time can affect the measured response, so suitable controls are essential.
Comparative peptide studies should use defined endpoints rather than assuming that broader activity produces a better outcome.
Handling, Preparation and Storage
Follow the instructions for the exact material supplied. A lyophilised peptide and a prepared solution may require different conditions, and neither should be assigned a universal shelf life without supporting stability data.
Before preparation, confirm the solvent and concentration required by the validated protocol. Record preparation dates, storage conditions and any relevant observations.
Clinical trial schedules should not be repurposed as instructions for a research reagent. Material labelled for research use is not suitable for personal administration or clinical treatment.
What to Check Before You Buy Retatrutide
When assessing a supplier for laboratory research, prioritise traceable identity and analytical evidence. Request the batch-specific certificate of analysis (COA) and check that it matches the product label.
Useful documentation includes:
- Identity results consistent with the expected peptide.
- Purity results with the analytical method clearly identified.
- Evidence supporting the labelled quantity.
- Relevant storage and preparation instructions.
- Independent third-party reports where such testing is advertised.
HPLC purity is commonly reported as a peak-area percentage. This does not independently establish peptide content, sterility or biological performance. Mass spectrometry provides complementary identity information, but its results must also be interpreted using the stated method.
A COA should be assessed against the intended assay, not treated as a blanket guarantee. Ask the supplier to explain missing or inconsistent results before selecting the material.
Research Outlook and Intended Use
Retatrutide continues to be investigated in programmes addressing obesity, type 2 diabetes and related conditions. Published results and ongoing studies will inform its clinical assessment; positive findings alone do not constitute approval.
For controlled experiments, reliable peptide selection depends on verified composition, appropriate methods and reproducible preparation. Any separately marketed laboratory material must be evaluated on its own documentation rather than assumed equivalent to the clinical investigational product.
The research-use designation does not authorise administration to people or animals.
Related studies:
Product Specifications
- Form: Lyophilized powder
- Purity: ≥98% (class-level specification)
- Storage: −20°C, protected from light
- Intended use: Laboratory research only
- Documentation: Batch certificate of analysis on request
COA Analysis
Selected lots are independently tested. Request the certificate for your batch number before the material enters an assay. Identity should match the stated sequence on the vial label.
For research purposes only. Not for human consumption.
Handling & Storage
Check the lot number against the certificate before the material enters an assay. Reconstitute only when the protocol calls for a working solution, using the solvent and concentration that protocol specifies. A prepared solution is not assumed to have the same storage life as the dry vial.
Store sealed vials at −20°C, protected from light and moisture. For research use only. Not for human or animal administration.
